Rayner Launches the Plus1 EMV Campaign on Monovision Education

With the global rollout of the RayOne EMV IOL to markets around the world, Rayner announced a new campaign intended to extoll the benefits of monovision (including “Mini”, “Micro”, or “Blended”).

“The Plus1 EMV: A global discussion on Enhanced Monovision campaign” will shine a light on what is the most frequently used method for correcting presbyopia in cataract and laser vision surgery, with monovision globally accounting for 25 percent of procedures[1]. Yet many surgeons steer away from using the term “monovision.”

“We intend to start a conversation with ophthalmologists about monovision and encourage more surgeons to embrace this highly accurate, cost-effective method for treating presbyopia,” Christopher Willis, Rayner Global Vice President of Marketing, said in a company news release.

Global Campaign

Plus1 EMV will take the message of monovision to a global level. To develop and manage the campaign, Rayner has partnered with Medevise Consulting, a Strasbourg, France-based consulting company with a team that has extensive experience with presbyopic technologies, as well as introducing innovative products to market.

“We are excited to be partnering with the Rayner team on Plus1 EMV due to its singular focus on the benefits of monovision,” said Kristine A. Morrill, President and founder of Medevise.

Working alongside the Rayner and Medevise teams will be a global group of surgeons who also embrace monovision, including Professor Graham Barrett, who worked with Rayner to develop the RayOne EMV IOL, to help spread the word.

Launching this month, the Plus1 EMV campaign will use a variety of tools to accomplish this, including symposiums and webinars, as well as in-person meetings, when possible. The Plus1 EMV campaign coincides with the first U.S. implantations of the RayOne EMV IOL by Robert Weinstock, MD (Largo, FL), William Wiley, MD (Cleveland, Ohio), Vance Thompson, MD, (Sioux Falls, SD), and Phillips Kirk Labor, MD, (Dallas, TX).